株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

下肢静止不能症候群治療薬の世界市場:2015〜2019年

Global Restless Legs Syndrome Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 332644
出版日 ページ情報 英文 80 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
下肢静止不能症候群治療薬の世界市場:2015〜2019年 Global Restless Legs Syndrome Market 2015-2019
出版日: 2015年06月10日 ページ情報: 英文 80 Pages
概要

下肢静止不能症候群(RLS)は神経疾患で、肢に不快な痛みを伴うため、患者の睡眠パターンの障害につながっています。男女ともにみられ、すべての年齢で発症しますが、中年〜高齢者に多いものとなっています。現在のところ特定の治療法はなく、市場に出ている薬剤は症状を和らげるものです。世界の下肢静止不能症候群市場は、2014〜2019年にかけCAGR11.46%で拡大すると予測されています。

当レポートでは、世界の下肢静止不能症候群治療薬市場について詳細に分析し、市場の動向と2015〜2019年の成長見通し、製品概要とパイプライン分析、地域別動向、および主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 当レポートの範囲

第4章 調査方法

第5章 製品プロファイル

  • Mirapex/Sifrol/Mirapexin
  • Requip
  • Neupro/Leganto
  • HORIZANT/Regnite

第6章 イントロダクション

第7章 疾患の概要

  • RLSの理解
  • 病因
  • 徴候と症状
  • 診断
  • 管理
  • 疫学
  • 経済的負担

第8章 パイプライン分析

  • パイプライン候補に関する重要情報

第9章 商業的機会

第10章 主要ブランド分析

第11章 市場環境

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第12章 薬剤クラス別市場セグメンテーション

  • ドーパミン作動薬
  • オピオイド
  • 抗痙攣剤
  • 鎮静剤および睡眠薬
  • その他

第13章 地域別セグメンテーション

第14章 購入基準

第15章 市場成長促進因子

第16章 促進因子とその影響

第17章 市場の課題

第18章 促進因子と課題の影響

第19章 市場動向

第20章 動向とその影響

第21章 ベンダー環境

  • 競合シナリオ
  • 市場シェア調査:2014年
  • その他の将来的見込みのあるベンダー

第22章 主要ベンダー調査

  • Boehringer Ingelheim
  • GlaxoSmithKline
  • UCB
  • XenoPort

第23章 当シリーズの他のレポート

目次
Product Code: IRTNTR6054

About RLS

RLS is a neurological disease; it is also known as Willis-Ekbom disease. People with RLS experience an overwhelming desire to move their legs. It leads to an unpleasant pain in the limbs, leading to a disturbance in sleep pattern of patients. The condition aggravates at night or when the person is at rest. It occurs in both genders, but higher prevalence is seen in women than men. It affects people of all ages but mostly affecting the middle-aged and elderly people. Its common symptoms are uncomfortable itching pain in the legs, leading to a disruption in the sleep pattern and ultimately affecting the quality of life of individuals. The precise cause of RLS is not known but with the extensive investigations done in the field, it is believed to be due to predisposing genetic factors or due to low levels of iron in the brain or due to the disturbances in the dopaminergic balance. Till date, there is no specific cure for the disorder. The drugs present in the market help in the symptomatic treatment of the disorder and in relieving the uneasiness caused due to this disorder.

Technavio's analysts forecast the global RLS market to grow at a CAGR of 11.46% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global RLS market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of RLS.

Technavio's report, the Global RLS Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and APAC and EMEA; it also covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Boehringer Ingelheim
  • GlaxoSmithKline
  • UCB
  • XenoPort

Other Prominent Vendors

  • Alexza Pharmaceuticals
  • Astellas Pharma
  • Axxonis Pharma
  • Bayer Healthcare
  • Impax Pharmaceuticals
  • Luitpold Pharmaceuticals
  • Merz Pharmaceuticals
  • Mundipharma
  • Newron Pharmaceuticals
  • Serina Therapeutics
  • Teva Neuroscience

Market driver

  • High unmet medical needs
  • For a full, detailed list, view our report

Market challenge

  • Unknown disease etiology
  • For a full, detailed list, view our report

Market trend

  • Expected entry of drugs with multiple mechanisms and novel technologies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Product Profiles

  • 05.1. Mirapex/Sifrol/Mirapexin
  • 05.2. Requip
  • 05.3. Neupro/Leganto
  • 05.4. HORIZANT/Regnite

06. Introduction

07. Disease Overview

  • 07.1. Understanding RLS
    • 07.1.1. Types of RLS
  • 07.2. Etiology and Pathogenesis
    • 07.2.1. Genetic Factors
    • 07.2.2. Iron Deficiency
    • 07.2.3. Other Disease Conditions/Medications
    • 07.2.4. Neurological Disturbances
  • 07.3. Signs and Symptoms
  • 07.4. Diagnosis
    • 07.4.1. Differential Diagnosis of RLS
  • 07.5. Management
    • 07.5.1. Pharmacological Therapy
    • 07.5.2. Non-pharmacological Therapy
  • 07.6. Epidemiology
  • 07.7. Economic Burden

08. Pipeline Analysis

  • 08.1. Key Information on Pipeline Candidates
    • 08.1.1. Injectafer
    • 08.1.2. Lisuride
    • 08.1.3. Incobotulinumtoxin A
    • 08.1.4. IPX-159
    • 08.1.5. Safinamide
    • 08.1.6. AZ-008
    • 08.1.7. SER-214

09. Commercial Opportunities

10. Key Brand Analysis

11. Market Landscape

  • 11.1. Market Overview
  • 11.2. Market Size and Forecast
  • 11.3. Five Forces Analysis

12. Market Segmentation by Class of Drugs

  • 12.1. Dopaminergic Drugs
  • 12.2. Opioids
  • 12.3. Anticonvulsants
  • 12.4. Sedatives and Hypnotics
  • 12.5. Others

13. Geographical Segmentation

  • 13.1. Global Restless Legs Syndrome Market by Geography 2014-2019

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2014
    • 21.2.1. UCB
    • 21.2.2. GlaxoSmithKline
    • 21.2.3. Boehringer Ingelheim
    • 21.2.4. XenoPort
  • 21.3. Other and Future Prominent Vendors

22. Key Vendor Analysis

  • 22.1. Boehringer Ingelheim
    • 22.1.1. Key Facts
    • 22.1.2. Business Overview
    • 22.1.3. Business Segmentation by Revenue 2013
    • 22.1.4. Business Segmentation by Revenue 2012 and 2013
    • 22.1.5. Geographical Segmentation by Revenue 2013
    • 22.1.6. Business Strategy
    • 22.1.7. Recent Developments
    • 22.1.8. SWOT Analysis
  • 22.2. GlaxoSmithKline
    • 22.2.1. Key facts
    • 22.2.2. Business overview
    • 22.2.3. Business segmentation by revenue 2014
    • 22.2.4. Business segmentation by revenue 2013 and 2014
    • 22.2.5. Geographical segmentation by revenue 2014
    • 22.2.6. Business strategy
    • 22.2.7. Recent developments
    • 22.2.8. SWOT analysis
  • 22.3. UCB
    • 22.3.1. Key Facts
    • 22.3.2. Business Overview
    • 22.3.3. Product Segmentation by Revenue 2013
    • 22.3.4. Product Segmentation by Revenue 2012 and 2013
    • 22.3.5. Geographical Segmentation by Revenue 2013
    • 22.3.6. Business Strategy
    • 22.3.7. Recent Developments
    • 22.3.8. SWOT Analysis
  • 22.4. XenoPort
    • 22.4.1. Key Facts
    • 22.4.2. Business Overview
    • 22.4.3. Business Strategy
    • 22.4.4. SWOT Analysis

23. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Types of RLS
  • Exhibit 3: Prevalence of Primary and Secondary RLS 2014
  • Exhibit 4: Types of RLS based on Onset of Disease
  • Exhibit 5: Etiology of RLS
  • Exhibit 6: Symptoms of RLS
  • Exhibit 7: Differential Diagnosis of RLS
  • Exhibit 8: Treatment Options for RLS
  • Exhibit 9: Prevalence of RLS Based on Gender
  • Exhibit 10: Pipeline Portfolio of Global Restless Legs Syndrome Market
  • Exhibit 11: Commercial Opportunities for Global Restless Legs Syndrome Market
  • Exhibit 12: Global Restless Legs Syndrome Market 2014-2019 ($ millions)
  • Exhibit 13: Global Restless Legs Syndrome Market by Class of Drugs
  • Exhibit 14: Global Restless Legs Syndrome Market by Geography 2014
  • Exhibit 15: Vendor Ranking 2014
  • Exhibit 16: Neupro: YoY Growth Rate and Revenue 2010-2014 ($ millions)
  • Exhibit 17: Neupro: Region-wise Revenue Comparison 2012-2014 ($ millions)
  • Exhibit 18: Requip: YoY Growth Rate and Revenue 2010-2014 ($ millions)
  • Exhibit 19: Region-wise Revenue Comparison of Requip 2012-2014 ($ millions)
  • Exhibit 20: HORIZANT: US Revenue 2013-2014 ($ millions)
  • Exhibit 21: Regnite: Revenue in Japan 2013-2014 ($ millions)
  • Exhibit 22: Boehringer Ingelheim: Business Segmentation by Revenue 2013
  • Exhibit 23: Boehringer Ingelheim: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 24: Boehringer Ingelheim: Geographical Segmentation by Revenue 2013
  • Exhibit 25: GlaxoSmithKline: Business segmentation by revenue 2014
  • Exhibit 26: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
  • Exhibit 27: GlaxoSmithKline: Geographical segmentation by revenue 2014
  • Exhibit 28: UCB: Product Segmentation by Revenue 2013
  • Exhibit 29: UCB: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 30: UCB: Geographical Segmentation by Revenue 2013
Back to Top